Genentech’s Alecensa Joins The ALK Inhibitor Market
This article was originally published in The Pink Sheet Daily
Alectinib will launch within two weeks for second-line ALK-positive non-small lung cancer at the price of $12,500 per month.
You may also be interested in...
The firm got off to a solid start in 2016, which should see its biggest launches in years, but its core strength remains executing long-term management of its key franchises.
New indication now allows use in non-small cell lung cancer patients with rare ROS-1 genetic alterations.
FDA grants accelerated approval to ceritinib following a four-month review. The ALK inhibitor is indicated for non-small cell lung cancer patients who have progressed on or are intolerant of Pfizer’s Xalkori.